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p66(Shc) at Ser36, augments reactive oxygen species production via nicotinamide adenine dinucleotide
phosphate oxidase, and in turn reduces nitric oxide bioavailability. This novel molecular pathway may
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Hypertension is an established risk factor for the develop-ment of cerebrovascular and cardiovascular disease1–3; 
in patients with hypertension, each increase of 1 mm Hg in 
blood pressure corresponds to a 1% increase in stroke mortal-
ity.4 Hypertension exerts its deleterious effects on the vessel 
wall mainly via mechanical forces such as shear stress and 
cyclic stretch.5 Under physiological conditions, mechanical 
forces are crucial for the maintenance of vascular cell homeo-
stasis6; however, pathologically increased mechanical forces, 
as observed in hypertension, lead to adaptive changes in vas-
cular cells that may cause endothelial dysfunction and vascu-
lar disease.7
During the past years, several studies have demonstrated 
an increased production of reactive oxygen species (ROS) by 
endothelial cells exposed to pathological cyclic stretch.8–10 An 
increased production of ROS perturbs the physiological redox 
balance, inducing oxidative stress resulting in inactivation of 
nitric oxide (NO).11 This in turn leads to endothelial dysfunc-
tion, a key step in the pathophysiology of many cardiovascular 
diseases.12
p66Shc belongs to the mammalian Shc adaptor pro-
tein family,13,14 participates in ROS production,15–19 and 
is involved in translation of oxidative stimuli into apop-
tosis.20,21 Genetic deletion of p66Shc in mice was shown 
to improve endothelial function in different disease mod-
els.15,16,18 In particular, p66Shc mediates vascular dysfunction 
observed in angiotensin II–treated, hypertensive mice.22 
Nevertheless, the role of p66Shc in mediating the deleterious 
effects of pathological cyclic stretch on the vasculature is 
not known.
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The present study was designed to characterize the role of 
p66Shc in cyclic stretch–induced endothelial damage. In particu-
lar, we assessed whether p66Shc mediates the increased superox-
ide anion (O2−) production and the decreased NO bioavailability 
observed in endothelial cells exposed to pathological cyclic 
stretch. Finally, to assess the relevance of our findings in vivo, we 
explored whether p66Shc activation is increased in isolated aortic 
endothelial cells of spontaneously hypertensive rats (SHR).
Materials and Methods
Detailed Materials and Methods are available in the online-only Data 
Supplement.
Cell Culture Experiments
For all in vitro experiments, primary human aortic endothelial cells 
(HAECs; Lonza) from passages 6 to 9 were used. Detailed Methods 
are provided in the online-only Data Supplement.
siRNA Transfection
Cells were transfected with predesigned small interfering RNA 
(siRNA) against p66Shc using N-TER Nanoparticle siRNA 
Transfection System (Sigma-Aldrich) or by using Lipofectamine 
RNAiMAX Reagent (Invitrogen). Detailed Methods are provided in 
the online-only Data Supplement.
Application of Cyclic Stretch
Cyclic stretch to adhering cells on BioFlex culture plates (Flexcell 
International) was applied using the Flexcell FX-4000T system 
(Flexcell International). Detailed Methods are provided in the online-
only Data Supplement.
Immunoblotting
Protein expression and activation were determined by immunoblot 
analysis. Cells were lysed in lysis buffer, and equal amounts of pro-
tein were separated by SDS-PAGE. Detailed Methods are provided in 
the online-only Data Supplement.
Measurement of O2− Production and NO 
Bioavailability
O2− production and NO bioavailability in intact cells or aortic tis-
sue were determined using electron spin resonance spectroscopy. 
Detailed Methods are provided in the online-only Data Supplement.
NADPH Oxidase Activity Measurement
Determination of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase activation was performed using a commercially 
available kit (Abcam) and performed according to the manufacturer’s 
recommendations.
Animal Experiments
Sixteen-week-old male SHR and male Wistar-Kyoto (WKY) rats 
were purchased from Janvier Laboratories. Study design and experi-
mental protocols were approved by the Cantonal Veterinary Office of 
the Canton of Zurich. Detailed Methods are provided in the online-
only Data Supplement.
Statistical Analysis
Data are presented as mean±SEM. Statistical analysis for compari-
son of 2 groups was performed using 2-tailed unpaired Student t 
test or Mann–Whitney test when appropriate. For comparison of >2 
unmatched groups, 1-way ANOVA followed by the Bonferroni post 
hoc test or Kruskal–Wallis test followed by the Dunn post hoc test 
was performed when appropriate. A value of P<0.05 denoted a signif-
icant difference. Statistical analysis was performed using GraphPad 
Prism software 5.01.
Results
Cyclic Stretch Enhances p66Shc Activation in a 
Stretch- and Time-Dependent Manner
Exposure of HAECs to pathological cyclic stretch (8% and 
15% stretch) for 6 hours resulted in a stretch-dependent 
increase in p66Shc phosphorylation at Ser36 compared with 
static condition, whereas no change in p66Shc activation was 
observed under physiological stretch (2%; Figure 1A). In 
addition, the extent of p66Shc activation was time-dependent 
as observed after exposure of HAECs to 1, 3, or 6 hours of 
pathological cyclic stretch (Figure 1B). All conditions did 
not change p66Shc protein expression (Figure 1A and 1B). 
To exclude potential cytotoxic effects of pathological cyclic 
stretch, a colorimetric assay for detection of lactate dehydro-
genase release was performed. No cytotoxicity was observed 
when cells were exposed to pathological cyclic stretch com-
pared with static condition (data not shown).
MAPK JNK1/2 Mediates Pathological Stretch–
Increased p66Shc Activation
Immunoblot analysis revealed an enhanced activation of the 
mitogen-activated protein kinases (MAPKs) c-Jun N-terminal 
kinase (JNK) 1/2 (Figure 2A), p38, and extracellular signal–
regulated kinase (ERK) 1/2 (data not shown) after exposure 
of HAECs to pathological stretch. Differently, no change in 
the phosphorylation (at T641) of protein kinase C βII was 
observed (data not shown). To characterize intracellular sig-
naling pathways mediating pathological stretch–increased 
p66Shc activation, MAPK JNK1/2, p38, or ERK1/2 was 
inhibited by incubating HAECs with SP600125 (1 µmol/L), 
SB203580 (1 µmol/L), or PD98059 (1 µmol/L), respectively, 
Figure 1. Effect of cyclic stretch on p66Shc activation. A, 
Pathological cyclic stretch (8% and 15%; n=6), but not 
physiological stretch (2%; n=6), leads to an increased p66Shc 
phosphorylation at Ser36. B, Human aortic endothelial cells 
exposed to 15% of cyclic stretch show a time-dependent 
increase in p66Shc activation (n=6–7). *P<0.05 for stretch vs 
control. Ctrl indicates control (static condition).
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before exposure to pathological stretch. Inhibition of JNK1/2 
prevented stretch-increased p66Shc activation (Figure 2B). In 
contrast, this was not observed when p38 or ERK1/2 was 
inhibited (data not shown). To assess whether p66Shc activation 
in response to pathological cyclic stretch occurs upstream or 
downstream of JNK1/2, the effect of p66Shc silencing on path-
ological stretch–increased JNK1/2 activation was assessed. 
Preincubation of HAECs with siRNA-specific targeting p66Shc 
did not affect JNK1/2 activation and JNK1/2 protein levels 
under pathological stretch condition (Figure 2C), indicating 
that p66Shc acts as a downstream target of JNK1/2 when cells 
are exposed to pathological cyclic stretch.
JNK1/2, p66Shc, and NADPH Oxidase Mediate 
Pathological Stretch–Increased O2− Production and 
Stretch-Reduced NO Bioavailability
To assess the effect of p66Shc silencing or JNK1/2 inhibi-
tion on stretch-increased O2− production and stretch-reduced 
NO bioavailability, HAECs were transfected with siRNA-
specific targeting p66Shc or pretreated with SP600125 (1 
µmol/L). Silencing of p66Shc or JNK1/2 inhibition reduced 
stretch-increased O2− generation (Figure 3A) and resulted in 
an increased NO bioavailability under pathological stretch 
condition (Figure 3C). Furthermore, p66Shc silencing reduced 
stretch-increased NADPH oxidase activity (Figure 3B). 
Previously, a role for p66Shc in inhibiting endothelial NO 
synthase (eNOS)–dependent NO production was demon-
strated.23 Here, we investigated the potential effect of p66Shc 
silencing on eNOS under pathological stretch condition. 
Immunoblotting did not reveal any influence of p66Shc silenc-
ing under stretch condition on both Ser1177 (Figure 3D) and 
Thr495 (Figure 3E) phosphorylation sites of eNOS or on 
eNOS protein expression (Figure 3D and 3E).
Functional Integrin α5β1 Inhibition Diminishes 
Both p66Shc and JNK1/2 Activation Increased by 
Pathological Stretch
Integrins are known to translate extracellular mechanical stim-
uli into intracellular adaptations.24 To address the role of inte-
grin α5β1 in pathological stretch–increased p66Shc activation, 
its function was blocked using an anti-integrin α5β1 antibody25 
(10 µg/mL) before pathological stretch exposure. Thereby, 
pathological stretch–increased p66Shc activation was reduced 
(Figure 4A). In line with this, pathological stretch–increased 
JNK1/2 activation was decreased by functional integrin α5β1 
inhibition (Figure 4B).
p66Shc Activation Is Elevated in the Endothelium of 
Hypertensive Rats
To test the physiological relevance of the data obtained in 
vitro, regulation of p66Shc was studied in vivo by assessing its 
activation in aortic endothelial cells of SHR compared with 
normotensive WKY rats. Blood pressure monitoring showed 
elevated systolic blood pressures in SHR compared with 
WKY rats, whereas no difference in heart rate was observed 
(data not show). Immunoblot analysis revealed an increase 
in p66Shc phosphorylation at Ser36 in aortic endothelial cells 
of SHR compared with WKY rats, without showing altered 
p66Shc protein expression (Figure 5A). In addition, in aortic 
homogenates of SHR, we observed an increased O2− genera-
tion (Figure 5B) as well as a reduction in NO bioavailability 
(Figure 5C) compared with WKY.
Discussion
This study demonstrates for the first time that pathological 
cyclic stretch causes an increased endothelial O2− produc-
tion and a reduced NO bioavailability through the activation 
of the adaptor protein p66Shc downstream of integrin α5β1 and 
JNK1/2 and upstream of the NADPH oxidase. Next, we con-
firm that p66Shc activation is increased also in isolated aortic 
endothelial cells of SHR compared with WKY rats.
Vascular cells are constantly exposed to mechanical forces, 
such as shear stress and cyclic stretch.5 The location of inte-
grins between the extracellular matrix and intracellular cyto-
skeleton elements assigns them an important function as 
mechanotransducers.26,27 Integrins were shown to be crucial in 
translating pathologically increased mechanical stimuli into 
morphological and intracellular adaptations.24,28 In this study, 
we focused on investigating the role of α5β1 integrin, which is 
known to be abundantly expressed in endothelial cells29 and to 
adhere to fibronectin.30 Functional blockade of integrin α5β1 
abolished pathological stretch–increased p66Shc phosphoryla-
tion and JNK1/2 activation, demonstrating that integrin α5β1 
acts as a key mechanotransducer for the pathological endothe-
lial adaptations observed in the present study (Figure 6).
Pathways mediating extracellular signals to crucial endo-
thelial proteins may involve protein kinase C31 and the MAPKs 
JNK, p38, and ERK.32 A role for protein kinase C33 and 
Figure 2. Mitogen-activated protein kinase 
c-Jun N-terminal kinase 1/2 (JNK1/2) 
mediates pathological stretch–increased 
p66Shc activation. A, Pathological stretch 
leads to an increase in the activation of 
JNK1/2 (n=6). B, Pretreatment of human 
aortic endothelial cells with the specific 
JNK1/2 inhibitor SP600125 (1 µmol/L) 
abolishes pathological stretch–increased 
p66Shc activation (n=6). C, Stretch-
increased JNK1/2 activation is not altered 
after silencing of p66Shc (n=6). *P<0.05 for 
stretch vs control; #P<0.05 for stretch with 
SP600125 vs stretch alone. Ctrl indicates 
control (static condition); p-JNK1/2, 
phosphorylated JNK1/2; and scr siRNA, 
scrambled small interfering RNA.
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MAPKs34 in endothelial cell adaptations induced by patholog-
ical cyclic stretch has been reported previously. Furthermore, 
JNK is a known activator of p66Shc after stimulation of endo-
thelial cells with oxidized low-density lipoprotein.35 Unlike 
protein kinase C βII, phosphorylation of JNK1/2, p38, and 
ERK1/2 was enhanced after exposure to pathological stretch. 
However, only inhibition of JNK1/2, and not inhibition of p38 
or ERK1/2, blunted p66Shc activation and O2− production and 
restored NO bioavailability after pathological stretch, thus 
indicating a pivotal role for JNK1/2 in these settings.
An increased level of endothelial ROS after patho-
logical stretch exposure, as observed in our study, is in 
line with previous investigations.8,9 A balance between 
ROS production and degradation is essential to maintain 
Figure 4. Role of integrin α5β1 on pathological stretch–increased 
p66Shc and c-Jun N-terminal kinase 1/2 (JNK1/2) activation.  
A and B, Functional integrin α5β1 blocking abolishes p66
Shc 
(n=5–6) and JNK1/2 (n=7–8) activation induced by pathological 
stretch. *P<0.05 for stretch vs control; #P<0.05 for stretch with 
antiα5β1 vs stretch alone. Ctrl indicates control (static condition); 
and p-JNK1/2, phosphorylated JNK1/2.
Figure 5. p66Shc activation in aortic endothelial cells of Wistar-
Kyoto (WKY) rats and spontaneously hypertensive rats (SHR). 
A, Immunoblot analysis reveals an increase in p66Shc activation 
(n=4–6) in aortic endothelial cells of hypertensive rats compared 
with normotensive ones. B and C, SHR show elevated levels of 
O2
− (n=6) and reduced nitric oxide (NO) bioavailability (n=6) in 
aortic homogenates compared with WKY rats. *P<0.05, **P<0.01 
for SHR vs WKY.
Figure 3. p66Shc silencing and c-Jun N-terminal kinase 1/2 (JNK1/2) inhibition abolish pathological cyclic stretch–increased O2
− production 
and increases pathological stretch–reduced nitric oxide (NO) bioavailability. A, Pretreatment of human aortic endothelial cells with specific 
small interfering RNA (siRNA) against p66Shc or with the pharmacological JNK1/2 inhibitor SP600125 (1 µmol/L) reduces pathological 
stretch–increased O2
− production (n=6–12). B, Pathological stretch–increased nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase activity is significantly reduced after silencing of p66Shc (n=4). C, Both p66Shc silencing and JNK1/2 inhibition increase NO 
bioavailability under pathological stretch condition (n=6). p66Shc silencing does not alter endothelial NO synthase (eNOS) phosphorylation 
at Ser1177 (n=7; D) and Thr495 (n=4; E) or eNOS protein expression under stretch condition. *P<0.05, **P<0.01, ***P<0.001 for stretch vs 
control; #P<0.05, ##P<0.01 for stretch with p66Shc silencing or SP600125 vs stretch alone. Ctrl indicates control (static condition); p-eNOS, 
phosphorylated endothelial NO synthase; and scr siRNA, scrambled small interfering RNA.
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physiological cellular processes and function,21 and the 
perturbation of this redox balance, by an increased ROS 
production and a decreased antioxidant capacity, induces 
oxidative stress resulting in endothelial dysfunction,21 a 
common denominator to many cardiovascular diseases, 
such as hypertension.36,37 Previously, NADPH oxidase has 
been demonstrated to be a major source for pathological 
stretch–increased O2− generation.8 Furthermore, NADPH 
oxidase was demonstrated to be a downstream target of 
p66Shc,35 thus NADPH oxidase may represent the source of 
stretch-increased O2− production downstream of p66Shc. In 
the present study, we showed that silencing of p66Shc pre-
vents stretch-increased NADPH oxidase activity, suggest-
ing that pathological stretch leads to an increase in p66Shc 
activation, which in turn activates NADPH oxidase and as 
a consequence increases O2− generation.
NO is a key mediator of endothelial function and thereby 
of vascular health.38 A large body of evidence indicates that 
hypertensive animals39–43 and patients with hypertension36,37 
are characterized by endothelial dysfunction. NO is rapidly 
inactivated by O2− to form peroxynitrite, exerting nitrosative 
stress to the cell.11 In line with a previous report,44 NO bio-
availability was decreased by pathological cyclic stretch that 
was, in the present study, prevented by p66Shc silencing, inde-
pendent of eNOS activation. This finding, together with the 
above described O2− data, supports the idea that the observed 
decrease in NO levels after pathological stretch is the result 
of the scavenging action of O2− on NO, rather than the result 
of a changed NO production, and in turn, the increased NO 
bioavailability on p66Shc silencing is the result of a decreased 
O2− production.
Finally, we studied the regulation of p66Shc in aortic endo-
thelial cells of SHR, whereby cyclic stretch is known to occur, 
to test the in vivo relevance of our in vitro data. In these set-
tings, we were able to confirm our in vitro findings by demon-
strating increased p66Shc activation in aortic endothelial cells 
of SHR compared with WKY rats. Furthermore, as observed 
in HAECs, we could confirm in aortic homogenates of SHR an 
increase in O2− production and a decrease in NO bioavailability 
compared with WKY rats underscoring that the pathways elu-
cidated in vitro are also relevant in vivo. These findings are 
in line with a previous study showing increased activation of 
p66Shc in the rat coarctation model of hypertension.45
Study Limitations
In the present study, we demonstrate an increased activation 
of p66Shc in aortic endothelial cells of hypertensive rats, where 
pathological cyclic stretch occurs. However, there is no clear 
evidence that this effect is mediated solely by increased cyclic 
stretch because other factors involved in hypertension, such as 
shear stress, occur in parallel in the vessels of SHR.
Perspectives
Hypertension is a major risk factor for myocardial infarction 
and stroke.1 One in 3 adults is diagnosed with hypertension,1 
thus a clear understanding of the molecular mechanisms 
underlying hypertension-induced vascular disease is essential 
for its prevention and treatment. The present study offers new 
insights into the signaling pathways that may be responsible 
for mediating the noxious effects of pathological cyclic stretch 
on endothelial function36,37 and demonstrates a crucial role of 
the adaptor protein p66Shc in this context.
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What Is New?
•	The adaptor protein p66Shc, on activation by c-Jun N-terminal kinase, 
mediates pathological cyclic stretch–increased O
2
− production and path-
ological cyclic stretch–decreased NO bioavailability.
What Is Relevant?
•	Patients with hypertension display endothelial dysfunction largely be-
cause of an increased reactive oxygen species production at the expense 
of a higher nitric oxide scavenging by O
2
−. Pathological cyclic stretch is 
partially responsible for this, and here we present a novel mediator that 
may be implicated in this phenomenon.
Summary
This study provides mechanistic insights into the signaling path-
ways activated by pathological cyclic stretch. In particular, we 
demonstrate a crucial role of p66Shc in mediating pathological 
cyclic stretch–increased superoxide anion production and patho-
logical cyclic stretch–reduced nitric oxide bioavailability. This novel 
molecular pathway may be relevant for endothelial dysfunction and 
vascular disease in hypertension.
Novelty and Significance
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Detailed Material and Methods 
 
Cell Culture Experiments 
Primary human aortic endothelial cells (HAECs) (Lonza) were cultured in EBM-2 
medium supplied with EGM-2 bullet kit (Lonza). For all experiments, adhering cells 
were grown to confluence on fibronectin-coated BioFlex® culture plates (Flexcell 
International) and rendered quiescent in EBM medium (Lonza) with 0.5% FBS. For all 
experiments, cells from passages 6 to 9 were used.  
To block the MAP kinases p38, extracelluar signal-regulated kinase p44/42 (ERK1/2), 
or c-Jun N-terminal kinase (JNK1/2), cells were treated with SB203580 (Sigma), 
PD98059 (Cell Signaling), or SP600125 (Calbiochem) respectively, before 
pathological stretch exposure. For functional integrin alpha5beta1 (α5β1) blocking, 
cells were pre-incubated with an anti-integrin α5β1 antibody (Millipore), before 
pathological stretch exposure.  
 
Small Interfering RNA (siRNA) Transfection 
Cells were transfected with predesigned siRNA targeting p66Shc (sense: 5′-
AUGAGUCUCUGUCAUCGCU[dT][dT]-3′; antisense: 5’-
AGCGAUGACAGAGACUCAU[dT][dT]-3’) (Sigma-Aldrich) using N-TER Nanoparticle 
siRNA Transfection System (Sigma-Aldrich) at final concentration of 10 nmol/L, or by 
using Lipofectamine®RNAiMAX Reagent (Invitrogen) at final concentration of 25 
nmol/L (for NADPH oxidase activity measurements), according to the manufacturer's 
protocol. siRNA incubation was performed using serum-free and antibiotics-free 
EBM-2 medium (Lonza) for 4 h, followed by 28 h of incubation in normal growth 
medium. As negative controls, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) siRNA (sense: 5′-GGUUUACAUGUUCCAAUAU[dT][dT]-3′; antisense: 5’-
AUAUUGGAACAUGUAAACC[dT][dT]-3’) (Sigma-Aldrich), scrambled siRNA (sense: 
5’-GAUCAUACGUGCGAUCAGA[dT][dT]-3’; antisense: 5’-
UCUGAUCGCACGUAUGAUC[dT][dT]-3’) (Sigma-Aldrich), and vehicle alone were 
used. 
 
Application of Cyclic Stretch 
Adhering cells on the flexible membrane of BioFlex® culture plates (Flexcell 
International) were exposed to different cyclic stretch (0.5 Hz) regimens (2%, 8%, or 
15%) with different interval times (1 h, 3 h, 6 h) using the Flexcell® FX-4000TTM 
system (Flexcell International). For all ROS, NO, and NADPH oxidase activity 
measurements as well as mechanistic experiments, a pathological stretch regimen of 
15% and 6 h was used. To assess cytotoxicity, a colorimetric assay (Roche) for 
detection of lactate dehydrogenase (LDH) release was used according to the 
manufacturer’s recommendations. 
 
Immunoblotting 
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Protein expression and activation was determined by immunoblot analysis. Cells 
were lysed in 50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L NaF, 
1 mmol/L DTT, 10 μg/μl aprotinin, 10 μg/μl leupeptin, 0.1 mmol/L Na3VO4, 1 mmol/L 
PMSF, and 0.5% NP-40. For analyzing protein kinase C beta II (PKCβ II) 
phosphorylation, cells were lysed in 20 mmol/L MOPS, 50 mmol/L β-glycerol 
phosphate, 50 mmol/L NaF, 10 μg/μL aprotinin, 10 μg/μL leupeptin, 1 mmol/L 
Na3VO4, 5 mmol/L EGTA, 2 mmol/L EDTA, 1 mmol/L DTT, 1 mmol/L PMSF, 1 
mmol/L benzamide, and 1% NP-40. Protein concentration was measured according 
to the manufacturer’s recommendations (Bio-Rad). Separation of proteins was done 
by SDS-PAGE, followed by the transfer to a polyvinylidene fluoride membrane 
(Millipore) by semidry transfer.  Antibodies against phosphorylated p38, ERK1/2, and 
JNK1/2 (all from Cell Signaling) were used at 1:1000, 1:5000, and 1:1000 dilution, 
respectively. Antibodies against p38, ERK1/2, and JNK1/2 protein expression (all 
from Cell Signaling) were used at 1:2000, 1:5000, and 1:1000 dilution, respectively. 
Anti-Shc/p66 (pSer36) antibody (Calbiochem) was used at 1:100 dilution. Anti-
pT641PKCβ II (Invitrogen) and anti-Shc (Cell Signaling, or BD Transduction 
LaboratoriesTM) antibodies were used at 1:1000 dilution. Anti-PKCβ II antibody 
(Santa Cruz) was used at 1:1000 dilution. Antibodies against p-eNOS (Thr495), p-
eNOS (Ser1177), and eNOS (all from BD Transduction LaboratoriesTM) were used at 
1:5000, 1:2000, and 1:2000 dilution. Immunoblots were normalized to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) (1:20000 dilution; Millipore) expression. Anti-
rabbit and anti-mouse secondary antibodies were purchased from SouthernBiotech.  
 
Measurement of O2- Production and NO Bioavailability 
O2− production was determined using electron spin resonance (ESR) spectroscopy, 
as previously described 1. Intact cells were suspended in Krebs-HEPES solution 
(Noxygen) containing 200 μmol/L 1-hydroxy-3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine hydrochloride (Noxygen), 5 μmol/L sodium 
diethyldithiocarbamate trihydrate (Noxygen), and 25 μmol/L deferoxamine 
methanesulfonate (Noxygen). On an ESR spectrometer (Bruker), O2- production was 
measured using following instrumental settings: center field, 3472.0 G; sweep width, 
10.00 G; microwave frequency, 9.76 GHz; microwave power, 19.91 mW; modulation 
frequency, 86.00 kHz; modulation amplitude, 2.60 G; and number of scans, 10. The 
temperature was set constant at 37° Celsius (temperature-controlled system). Aortic 
tissue of SHR and WKY rats was incubated with Krebs-HEPES solution (Noxygen) 
containing 500 μmol/L 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine 
hydrochloride (Noxygen), 5 μmol/L sodium diethyldithiocarbamate trihydrate 
(Noxygen), and 25 μmol/L deferoxamine methanesulfonate (Noxygen) for 1 h at 
37ºC. Samples frozen in liquid nitrogen were measured on an ESR spectrometer 
(Bruker) by using following instrumental settings: sweep width, 50.000 G; microwave 
frequency, 9.78 GHz; microwave power, 19.91 mW; modulation frequency, 86.00 
kHz; modulation amplitude, 2.60 G; and number of scans, 10. 
NO bioavailability was determined using ESR spectroscopy, as previously described 
1, 2. Fe(DETC)2 was formed by equal volumes of diethyldithiocarbonic acid sodium 
salt (7.2 mg/10 ml 0.9% NaCl) (Noxygen) and ferrous sulphate heptahydrate (4.5 
mg/10 ml 0.9% NaCl) (Noxygen). HAECs, or aortic tissue were incubated with Krebs-
HEPES – Fe(DETC)2 mixture for 1 h at 37ºC and then collected in Krebs-HEPES 
solution (Noxygen), followed by snap freezing in liquid nitrogen. Frozen samples 
were measured on an ESR spectrometer (Bruker) using following instrumental 
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settings: center field, 3455.00 G; sweep width, 80.00 G microwave frequency, 9.78 
GHz; microwave power, 39.72 mW; modulation frequency, 86.00 kHz; modulation 
amplitude, 10.34 G; and number of scans, 10. 
 
Animal Experiments 
Male spontaneously hypertensive rats (SHR) and male Wistar-Kyoto rats (WKY), all 
of which 16 weeks old, were purchased from Janvier Labs. Animals had ad libitum 
access to food (normal chow diet) and water, and were housed under a 12 h 
light/dark cycle. Following habituation training of the animals, systolic blood pressure 
(SBP) and heart rate (HR) measurements were performed by tail-cuff method (model 
LE 5002; Letica). Following anaesthesia by pentobarbital (50 mg/kg i.p.), animals 
were sacrificed by blood exsanguinations. Aortic tissue was then collected for 
measurement of O2- production and NO bioavailability, and rat aortic endothelial cells 
were isolated from the aorta for immunoblotting. Study design and experimental 
protocols were approved by the Cantonal Veterinary Office of the Canton of Zurich.   
 
Isolation of rat aortic endothelial cells 
Isolated aorta from SHR and WKY rats were quickly washed in Hanks’s Balanced 
Salt Solution (HBSS) (Invitrogen) containing 10 mmol/L HEPES and 0.1% BSA. Aorta 
were opened by a longitudinal cut and incubated on a culture dish (TPP®) treated 
with 0.4 % collagenase-dispase solution (Roche) for 35 min at 37°C. Resulting 
endothelial cell fraction was centrifuged for 5 min at 233 g and 4 °C. Pellet was 
resuspended in growth medium (DMEM (Life TechnologiesTM) containing 20% FCS, 
0.1 mg/ml heparin, 25 mmol/L HEPES, 1% non-essential amino acid (Sigma), 1% 
penicillin-streptomycin (PAA Laboratories GmbH), supplemented with 0.1 mg/ml of 
endothelium cell growth supplement (Sigma-Aldrich)), and plated on a culture dish 
(TPP®), pre-treated with 0.1% of gelatine of bovine skin origin (Sigma-Aldrich). Cells 
were cultured to confluence in growth medium and then lysed for immunoblotting. 
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Supplementary Figures     
  
 
 
Figure S1. Representative immunoblot of p66Shc silencing. Protein levels of 
p66Shc, but not of p52Shc and p46Shc, are selectively reduced after transfecting HAECs 
with specific siRNA against p66Shc. A, N-TER Nanoparticle siRNA Transfection 
System (Sigma-Aldrich). B, Lipofectamine®RNAiMAX Reagent (Invitrogen). scr 
siRNA indicates scrambled siRNA. 
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